ASP Isotopes Inc. · NASDAQ:ASPI
ASP Isotopes — Investor Presentation (March 2023)
29 slides from ASP Isotopes's investor presentation, March 2023
Slide 1: Corporate Overview
Corporate Overview March 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements”. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, fu
Slide 3: Introducing ASP Isotopes: Harvesting Nature’s Resources
Introducing ASP Isotopes: Harvesting Nature’s Resources ASPI aims to deliver reliable, cost-effective and a ASP technology is a low capital cost and politically acceptable supply of isotopes supply during environmentally friendly production of isotopes extended period of geopolitical uncertainty • I
Slide 4: What are isotopes?
What are isotopes? Isotopes are like identical twins or triplets: very similar in most aspects, except for subtle few differences. Molybdenum (Mo) has 7 stable isotopes, where Mo-100 content Isotopes are two or more types of atoms of the in the natural mix is only 10%. same chemical element that hav
Slide 5: Isotopes in Various End-Markets
Isotopes in Various End-Markets The separation of isotopes has been important during the past century, enabling key activities: • Improved medical diagnostic imaging and the treatment of various diseases and cancers • Generation of green nuclear energy • Advanced analytical methods for industrial ap
Slide 6: Renaissance of Isotopes: 1) Disruption and Shift in Supply
Renaissance of Isotopes: 1) Disruption and Shift in Supply Existing supply chains for established isotopes are fragile with a worsening outlook • Almost all (9 out 10) old nuclear reactors that currently produce the global supply of molybdenum-99 are expected to stop production during the next 10 ye
Slide 7: Renaissance of Isotopes: 2) Growth in Demand
Renaissance of Isotopes: 2) Growth in Demand Steady Historical Demand for medical isotopes has been growing at a stable rate of 4-5%/year, driven by aging population in many large countries and growth in medical diagnostics and procedures. Healthcare Drive long lasting, durable demand for medical is
Slide 8: Isotopes of Our Interest
Isotopes of Our Interest Ready for Under Commercially Isotopes End-Market R&D Stage Construction Construction Available Silicon-28 Quantum Computing Carbon-14 Pharma and Agrochem Molybdenum-100 Available in 2H'2023 Healthcare Molybdenum-98 Available in 2H'2023 Zinc-68 Ytterbium-176 Zinc-67 Healthcar
Slide 9: The world requires a new supplier of Carbon-14
The world requires a new supplier of Carbon-14 Russia has historically been responsible for the entire global supply of Carbon-14. Historically there have been supply side shortages. These have been exacerbated since the Feb 2022 Russian invasion of Ukraine. • There is an urgent need for enriched Ca
Slide 10: Mo-100 and Mo-98 are large opportunities
Mo-100 and Mo-98 are large opportunities Potential Reduction in Mo-99 supply due to planned retirement of old nuclear reactors 100% 80% 60% 40% 20% 0% 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 Upcoming Retirement of Majority (9 out of 10) Mo-99 Supplying Plants in the next 10 years Our
Slide 11: The world is at an inflection point for Silicon-28 demand
The world is at an inflection point for Silicon-28 demand • Our current plant in S. Africa is operational since 2018, produced several Kg of Si-28 enriched to 98%. • In anticipation of significant greater demand, we are in the early stages of constructing a larger, more powerful plant that will be c
Slide 12: Why Uranium is becoming interesting (again)
Why Uranium is becoming interesting (again) Increasing demand Energy Security Increasing focus on for nuclear fuel nuclear power US and European countries moving Many countries are looking to • UK plans to build 8 new nuclear power to revitalize nuclear industries become more self sustainable in pla
Slide 13: Our Contribution to US Commitment to SMR
Our Contribution to US Commitment to SMR • We believe that ASP technology is capable of enriching uranium. Current centrifuge technology that is employed to enrich uranium utilizes UF6 gas; our molybdenum enrichment facility will enrich MoF6 gas, which is similar to UF6. • For the production of HALE
Slide 14: Opportunities in Other Isotopes
Opportunities in Other Isotopes Zn-68 Important isotope in radio- Yb-176 - an important isotope for diagnostics oncology • Ytterbium-176 is emerging as a better method of producing • Zinc-68 can be converted to Gallium-68 in a Cyclotron. Lutetium-177, which is an emerging therapeutic. • Ga-68 dotata
Slide 15: Two Major Dimensions of ASPI
Two Major Dimensions of ASPI ASP Isotopes Inc. (Delaware, USA) ASP Isotopes Enriched Energy LLC • Low volume, high priced products • Higher volume, high value, medium priced products • Near-term focus is on Molybdenum-100 and Carbon 14. • New forms of Nuclear Energy will require new forms of fuel. C
Slide 16: Concluding Remarks
Concluding Remarks • ASPI is proven and proprietary technology platform for environmentally friendly production of a wide range of isotopes. ASPI is highly competitive due to its modular design, low capital cost and fast construction cycle vs. competitors. • Favorable long term market trends expecte
Slide 17: Supplemental Background Information
Supplemental Background Information • Company Leadership • More details on Isotopes • Tc-99 • Si-28 • Uranium Fuel (HALEU) for SMR 17
Slide 18: Leadership Team of ASP Isotopes
Leadership Team of ASP Isotopes Paul Mann, Chairman, CEO and CFO Paul Mann co-founded ASP Isotopes in September 2021 and serves as the Chairman of our Board of Directors, Chief Executive Officer and Chief Financial Officer. Paul has more than 20 years of experience on Wall Street investing in health
Slide 19: Senior Management Team
Senior Management Team Robert Ainscow, Interim Chief Financial Officer Robert Ainscow Co-founded ASP Isotopes Inc in September 2021 and serves as the Chief Financial Officer. He has more than 20 years experience in Finance, where he worked at Global Investment Banks Morgan Stanley, Bear Stearns and
Slide 20: Chief Scientific Advisor
Chief Scientific Advisor Einar Ronander , Chief Scientific Advisor Prof Einar Ronander is globally recognized as a leading scientist in the field of isotope separation for medical and industry production. He has over 50 years of experience in isotope separation which covers the mass spectrum from ve
Slide 21: Non-Employee Directors
Non-Employee Directors Duncan Moore, PhD, Director Duncan Moore, Ph.D. has served on our board of directors since October 2021. Duncan is a partner at East West Capital Partners since May 2008, which has a focus on making investments in the Healthcare Industry in Asia. Previously, from 1991 to 2008,
Slide 22: Map of Our Isotopes Interests
Map of Our Isotopes Interests Yb-176 and Xe-138 = C-14 and Si-28 = active consideration already produced Mo-100 and Mo-98 = plant in final stages Ni-64 and Zn-68 = of construction active consideration U-235, Li-6 and Cl-37 = Green Energy 22
Slide 23: ASP Technology creates Stable Isotopes more efficiently
ASP Technology creates Stable Isotopes more efficiently Traditional Technology ASP Differentiation Future Roadmap Expensive and Capital intensive Cost-effective proprietary design Enables long-term value capture • Traditionally, isotopes have • In separation, cylinder wall remains • ASP enrichment p
Slide 24: Advantage of ASP vs. Competing Technologies in U-235
Advantage of ASP vs. Competing Technologies in U-235 • ASPI has a robust, versatile platform of isotope enrichment technologies – which can offer solutions to the current problems of supply shortage and demand growth. • ASP enrichment plants are expected to have high profit margins and high return o
Slide 25: Tc-99m Supply Chain - In Need of an Alternative Supply Source
Tc-99m Supply Chain - In Need of an Alternative Supply Source • Tc-99m is produced from the radiological decay of Molybdenum- 99, which is usually created commercially by the fission of highly enriched uranium in a small number of research and material testing nuclear reactors in several countries M
Slide 26: Tc-99m can also be produced using Mo-100 or Mo-98
Tc-99m can also be produced using Mo-100 or Mo-98 • Tc-99m can be produced using Mo100 or Mo98 either directly or indirectly • Mo100 and Mo98 are stable and do not undergo radioactive decay; they can therefore be shipped and stored like traditional products, removing many supply chain issues associa
Slide 27: Silicon-28 … Enabling Quantum Computing
Silicon-28 … Enabling Quantum Computing Quantum Computers are expected to be 1000x more powerful than today’s conventional computers and widely anticipated they will create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics and other industries For the processi
Slide 28: SMR (Small Modular Reactors) = Next Wave in Nuclear Energy
SMR (Small Modular Reactors) = Next Wave in Nuclear Energy The world is moving to a new type of nuclear reactor: SMR TerraPower’s Natrium • Modular, smaller size (50 MWe to 300 MWe) reactors allowing greater flexibility in deployment • Designed for production-line manufacturing rather than conventio
Slide 29: HALEU Supply Issue Looming for SMR Reality
HALEU Supply Issue Looming for SMR Reality • Current commercial LWRs use low enriched uranium (LEU) which has less than 5% U-235 content. • Many SMRs and advanced reactors will require High Assay Low Enriched Uranium (HALEU) with U-235 enrichment up to 19.75%. • Currently there is no commercial sour